ATAI Life Sciences (ATAI) Price & Analysis

Compare

1,903 Followers

ATAI Stock Chart & Stats

$3.93

-$0.11(-6.29%)

At close: Jan 08 4:00 PM EST

$3.93

-$0.11(-6.29%)

Day’s Range― - ―

52-Week Range$1.15 - $6.75

Previous CloseN/A

Volume1.44M

Average Volume (3M)6.55M

Market Cap

$1.45B

Enterprise Value$1.04B

Total Cash (Recent Filing)$114.61M

Total Debt (Recent Filing)$2.96M

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Mar 26, 2026

EPS Estimate

-0.11

Last Dividend Ex-Date

Aug 27, 2018

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding363,190,520

10 Day Avg. Volume5,576,245

30 Day Avg. Volume6,549,885

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.83

Price to Sales (P/S)691.60

P/FCF Ratio-2.58

Enterprise Value/Market Cap0.72

Enterprise Value/Revenue344.47

Enterprise Value/Gross Profit-132.94

Enterprise Value/Ebitda-7.17

Forecast

1Y Price Target

$12.71

Price Target Upside223.41% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-0.61

Revenue Forecast (FY)$2.73M

Bulls Say, Bears Say

Bulls Say

Financial StabilityA recent raise means AtaiBeckley is well capitalized with a cash runway into 2029, which includes top-line data from a Phase 3 trial for BPL-003.

Market PotentialFor investors with a longer-term focus, ATAI is viewed as significantly undervalued relative to the size of the unmet need/market opportunity in the mental health-focused indications it is targeting.

Regulatory ProgressRegulatory alignment and Phase 3 initiation are anticipated as key catalysts, setting the stage for a pivotal year for the BPL-003 franchise.

Bears Say

Clinical RisksOne serious adverse event of suicidal ideation was reported, highlighting a potential risk factor in the treatment.

Regulatory And Competitive RisksRisks include clinical development risk tied to lead programs, competitor risk in relevant therapeutic areas, and government regulatory risk, such as the need to reschedule psychedelics.

ATAI Life Sciences News

Psychedelic: Atai Beckley, Cybin report quarterly earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

7d ago

PBM

ABBV

Atai Beckley reports Q3 EPS (28c), consensus (12c)

Reports Q3 revenue $749,000, consensus $55,560. “This has been a transformational quarter, highlighted by the establishment of AtaiBeckley,...

8d ago

ATAI

Atai Beckley sees cash runway into 2029

As of September 30, 2025, the Company had cash, cash equivalents and short-term securities of $114.6 million compared...

8d ago

ATAI

GH Research price target lowered to $35 from $40 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on GH Research (GHRS) to $35 from $40...

10d ago

ABBV

ATAI

Atai Beckley announces data from Phase 2b OLE study of BPL-003

Atai Beckley (ATAI) announced topline results from the open-label extension study of its Phase 2b clinical trial of...

10d ago

ATAI

Psychedelic: Compass Pathways, GH Research report Q3 earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

14d ago

PBM

ATAI

Atai Life Sciences completes combination between atai Life, Beckley Psytech

Atai Beckley announced the successful completion of the strategic combination between atai Life Sciences (ATAI) and Beckley Psytech...

15d ago

ATAI

Psychedelic: Compass Pathways, NeuroKaire enter R&D collaboration

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

21d ago

ATAI

CMND

Atai Life Sciences moved to Buy rating at Berenberg

Berenberg placed a Buy rating on Atai Life Sciences (ATAI) with a $12 price target saying the company...

27d ago

ATAI

Psychedelic: Clearmind enrolls last patient in first cohort of CMND-100 trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

28d ago

ATAI

CMND

AtaiBeckley: Strong Buy Rating Backed by Promising Clinical Data and Robust Financial Position

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on ATAI Life Sciences. The associated price...

19h ago

ATAI

ATAI Life Sciences’ BPL-003 Gains Momentum with Breakthrough Therapy Designation and Strategic Merger, Reinforcing Buy Rating

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on ATAI Life Sciences today and set a price...

7d ago

ATAI

ATAI Life Sciences: Promising Clinical Developments and Strong Financial Position Drive Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on ATAI stock, giving a Buy rating yesterday....

7d ago

ATAI

AtaiBeckley Advances Mental Health Therapies with FDA Milestone

Atai Life Sciences N.V. ( ($ATAI) ) has released its Q3 earnings. Here is a breakdown of the...

7d ago

ATAI

ATAI FAQ

What was ATAI Life Sciences’s price range in the past 12 months?

ATAI Life Sciences lowest stock price was $1.15 and its highest was $6.75 in the past 12 months.

What is ATAI Life Sciences’s market cap?

ATAI Life Sciences’s market cap is $1.45B.

When is ATAI Life Sciences’s upcoming earnings report date?

ATAI Life Sciences’s upcoming earnings report date is Mar 26, 2026 which is in 126 days.

How were ATAI Life Sciences’s earnings last quarter?

ATAI Life Sciences released its earnings results on Nov 12, 2025. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.165.

Is ATAI Life Sciences overvalued?

According to Wall Street analysts ATAI Life Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ATAI Life Sciences pay dividends?

ATAI Life Sciences pays a Notavailable dividend of $6 which represents an annual dividend yield of N/A. See more information on ATAI Life Sciences dividends here

What is ATAI Life Sciences’s EPS estimate?

ATAI Life Sciences’s EPS estimate is -0.11.

How many shares outstanding does ATAI Life Sciences have?

ATAI Life Sciences has 363,190,520 shares outstanding.

What happened to ATAI Life Sciences’s price movement after its last earnings report?

ATAI Life Sciences reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went down -2.257%.

Which hedge fund is a major shareholder of ATAI Life Sciences?

Currently, no hedge funds are holding shares in ATAI

ATAI Life Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

21.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ATAI Life Sciences

Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

ATAI Life Sciences (ATAI) Earnings & Revenues

Historic Earnings Reports

ATAI Stock 12 Month Forecast

Average Price Target

$12.71

▲(223.41% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.84,6.621538461538462,7.403076923076923,8.184615384615384,8.966153846153846,9.747692307692308,10.529230769230768,11.31076923076923,12.092307692307692,12.873846153846154,13.655384615384616,14.436923076923076,15.218461538461538,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.84,6.368461538461538,6.896923076923077,7.4253846153846155,7.953846153846154,8.482307692307693,9.010769230769231,9.53923076923077,10.067692307692308,10.596153846153847,11.124615384615385,11.653076923076924,12.181538461538462,{"y":12.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.84,6.16,6.4799999999999995,6.8,7.12,7.4399999999999995,7.76,8.08,8.4,8.719999999999999,9.04,9.36,9.68,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.08,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >